Okogen, Inc.
Okogen, Inc. is a clinical stage ophthalmic pharmaceutical company focused on developing a comprehensive treatment for both bacterial and viral acute infectious conjunctivitis.
Funding history
About Okogen, Inc.
How much funding has Okogen, Inc. raised?
Okogen, Inc. has raised $213K in total funding.
Where is Okogen, Inc. headquartered?
Okogen, Inc. is headquartered in Encinitas, CA.
What does Okogen, Inc. do?
Okogen, Inc. is a clinical stage ophthalmic pharmaceutical company focused on developing a comprehensive treatment for both bacterial and viral acute infectious conjunctivitis.
What problem does Okogen, Inc. solve?
Most conjunctivitis cases are treated with antibiotics regardless of the actual cause, and there are currently no approved treatments for adenoviral conjunctivitis, which makes up over 90% of viral eye infections.
What's Okogen, Inc.'s solution?
Developing a clinical-stage ophthalmic drug intended as a single treatment for all forms of acute infectious conjunctivitis, both bacterial and viral, currently in Phase 2B trials.
What makes Okogen, Inc. different?
Positions its lead candidate as a 'one stop shop' treatment covering both bacterial and viral conjunctivitis, an unmet need since no approved viral conjunctivitis therapy currently exists.
What makes Okogen, Inc. notable?
This San Diego ophthalmic biotech raised $10 million in Series A funding in 2018 from Brandon Capital's Medical Research Commercialisation Fund, and secured another $3.3 million in December 2024 to advance a Phase 2b trial for a pink-eye (acute infectious conjunctivitis) treatment.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
